生物醫學資訊研究所

Keyphrases

1. Taiwan 100%
2. National Cohort Study 54%
3. Confidence Interval 48%
4. Hepatocellular Carcinoma 21%
5. Population-based Cohort Study 20%
6. Hazard Ratio 20%
7. Support System 20%
8. Psoriasis 19%
9. Deep Learning 19%
10. Gastric Cancer 19%
11. Atopic Dermatitis 17%
12. Helicobacter Pylori (H. pylori) 16%
13. Helicobacter Pylori Infection 16%
14. COVID-19 15%
15. Bullous Pemphigoid 15%
16. CUD A 15%
17. Odds Ratio 14%
18. Machine Learning Algorithms 14%
19. Nursing 13%
20. Nursing Informatics 13%
21. Graphics Processing Unit 13%
22. Comorbidity 13%
23. Prediction Model 13%
24. Healthcare Professionals 12%
25. Radiofrequency Ablation 12%
26. Cumulative Incidence 12%
27. Risk Reduction 11%
28. Chronic Hepatitis B 10%
29. Medical Center 10%
30. China 10%
31. Performance Prediction 10%
32. Imiquimod 10%
33. Cancer Risk 10%
34. In Cancer 10%
35. Deep Learning Methods 9%
36. Imiquimod-induced 9%
37. Gut Microbiota 9%
38. Cancer Cells 9%
39. Genotype 9%
40. Inflammatory Bowel Disease 8%
41. Risk Factors 8%
42. Rosaceae 8%
43. Dupilumab 8%
44. Minimum Data Set 8%
45. Chronic Kidney Disease 8%
46. Randomized Controlled Trial 8%
47. U-Net 8%
48. Cloud Computing 8%
49. COVID-19 Cases 8%
50. Standardized Incidence Ratio 8%
51. Adjusted Hazard Ratio 8%
52. Excel VBA 8%
53. National Health Insurance 8%
54. Machine Learning 8%
55. Comparative Analysis 8%
56. Prediction Method 7%
57. Non-steroidal Anti-inflammatory Drugs (NSAIDs) 7%
58. Schizophrenia 7%
59. Systematic Meta-analysis 7%
60. COVID-19 Pandemic 7%
61. Artificial Neural Network 7%
62. High Risk 7%
63. Taipei 7%
64. Nested Case-control Study 7%
65. Malignancy 7%
66. Systems-based 7%
67. Protein Subcellular Localization Prediction 7%
68. COVID-19 Impact 7%
69. Low Risk 7%
70. Helicobacter Pylori Eradication 7%
71. Gut Microbiome 6%
72. Nucleos(t)ide Analogues 6%
73. Polymyositis 6%
74. GPGPU 6%
75. Dermatomyositis 6%
76. End-user Computing 6%
77. Area under the Receiver Operating Characteristic Curve 6%
78. Multivariate Analysis 6%
79. Taiwan National Health Insurance Research Database 6%
80. Vaccination 6%
81. Hepatocellular Carcinoma Recurrence 6%
82. Early Hepatocellular Carcinoma 6%
83. Prediction Accuracy 6%
84. Air Quality Index 6%
85. Magnetic Resonance Imaging 6%
86. National Health Insurance Research Database (NHIRD) 6%
87. Biological Characteristics 6%
88. Meta-analysis 6%
89. Microbiota 6%
90. Proton Pump Inhibitors 6%
91. Psoriatic Arthritis 6%
92. Taiwanese 6%
93. Fetal Growth Restriction 6%
94. Population-based 6%
95. Deep Learning Model 6%
96. Chronic Disease 6%
97. Liver Resection 6%
98. Indonesia 6%
99. Hepatitis C Virus 6%
100. Informatics 6%

Medicine and Dentistry

1. Cohort Analysis 58%
2. Hepatocellular Carcinoma 22%
3. Hazard Ratio 20%
4. Helicobacter Pylori 19%
5. Psoriasis 17%
6. Atopic Dermatitis 17%
7. Malignant Neoplasm 16%
8. Cancer 14%
9. Abdominal Cancer 14%
10. Infection 13%
11. Comorbidity 13%
12. Diseases 12%
13. Chronic Hepatitis B 12%
14. Bullous Pemphigoid 12%
15. Odds Ratio 11%
16. Breast Cancer 10%
17. Radiofrequency Ablation 10%
18. Gut Microbiota 10%
19. Case-Control Study 9%
20. COVID-19 9%
21. Liver Cirrhosis 8%
22. Cancer Risk 8%
23. Hepatectomy 8%
24. Rhinophyma 8%
25. Dupilumab 8%
26. Neoplasm 8%
27. Antiviral Therapy 8%
28. Gut 8%
29. Cumulative Incidence 7%
30. Chronic Kidney Disease 7%
31. Recurrent Disease 7%
32. Gut Microbiome 7%
33. Systematic Review 7%
34. Retrospective Cohort Study 7%
35. Inflammatory Bowel Disease 7%
36. Hepatitis B 6%
37. Chronic Disease 6%
38. Dermatomyositis 6%
39. Polymyositis 6%
40. Hepatitis B Antigen 6%
41. Hepatitis B Virus 6%
42. Dysbiosis 6%
43. Magnetic Resonance Imaging 6%
44. Cancer Cell 6%
45. Biological Product 6%
46. Standardized Incidence Ratio 6%
47. Nonsteroid Antiinflammatory Agent 6%
48. Diabetes 5%
49. Logistic Regression Analysis 5%
50. Fetus Growth 5%
51. Meta-Analysis 5%
52. Long-Term Care 5%
53. Stomach Acid 5%
54. Cardiovascular Disease 5%
55. Diabetes Mellitus 5%
56. Proportional Hazards Model 5%
57. Alanine Aminotransferase 5%
58. Prevalence 5%
59. Triage 5%
60. Skin Cancer 5%
61. Placebo 5%
62. Tenofovir Disoproxil 5%
63. Tumor Necrosis Factor 5%
64. Small for Gestational Age 5%
65. Prognostication 5%
66. Medical History 5%
67. Computer Assisted Tomography 5%
68. Nurse 5%